Who was studied?
One patient with HER2-positive, PD-L1-negative metastatic gastric adenocarcinoma.
What does the publication report?
A response after two cycles and progression-free survival of 6.5 months were reported.
Safety findings
The abstract does not provide a complete graded adverse-event profile.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report · DOI: 10.3389/fimmu.2024.1321946 · PMID: 38361930
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.